RT Journal Article
SR Electronic
T1 ISARIC Clinical Data Report issued: 14 July 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.17.20155218
DO 10.1101/2020.07.17.20155218
A1 ISARIC Clinical Characterisation Group
A1 Baillie, J Kenneth
A1 Baruch, Joaquin
A1 Beane, Abigail
A1 Blumberg, Lucille
A1 Bozza, Fernando
A1 Broadley, Tessa
A1 Burrell, Aidan
A1 Carson, Gail
A1 Citarella, Barbara
A1 Dagens, Andrew
A1 Dunning, Jake
A1 Elotmani, Loubna
A1 Escher, Martina
A1 Farshait, Nataly
A1 Garcia Barrio, Noelia
A1 Goffard, Jean-Christophe
A1 Hall, Matthew
A1 Hashmi, Madiha
A1 Horby, Peter
A1 Ignacio, Martin-Loeches
A1 Jassat, Waasila
A1 Jayakumar, Devachandran
A1 Kartsonaki, Christiana
A1 Kumar Vecham, Pavan
A1 Laouenan, Cedric
A1 Mentre, France
A1 Morton, Ben
A1 Munblit, Daniel
A1 Nekliudov, Nikita A.
A1 Nichol, Alistair D
A1 Oinam, Budhacharan Singh
A1 Ong, David
A1 Panda, Prasan Kumar
A1 Kumar Tirupakuzhi Vijayaraghavan, Bharath
A1 Lissauer, Samantha
A1 Pedrera Jimenez, Miguel
A1 Petrovic, Michele
A1 Ramakrishnan, Nagarajan
A1 Roger, Claire
A1 Rojek, Amanda
A1 Sandulescu, Oana
A1 Sharma, Pratima
A1 Somers, Emily C
A1 Streinu-Cercel, Anca
A1 Taccone, Fabio
A1 Ramos, Grazielle Viana
A1 Semple, Malcolm Gracie
A1 Sim Lim Heng, Benedict
A1 Wei, Jia
A1 Wils, Evert-Jan
A1 Wong, Xin Ci
A1 Olliaro, Piero L
A1 Merson, Laura
YR 2021
UL http://medrxiv.org/content/early/2021/09/10/2020.07.17.20155218.abstract
AB ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report, our 15th report, is a part of a series and includes the results of data analysis for data captured before 26 May 2021. The report marks a significant milestone – the submission of clinical data from over half a million individuals hospitalised with COVID-19. We thank all of the data contributors for their ongoing support.Data have been entered for 516,689 individuals from 788 partner institutions and networks, covering more than 1600 sites across 61 countries. This is a significant increase in data volumes and contributing countries since our most recent report dated 08 April 2021.The comprehensive analyses detailed in this report includes hospitalised individuals of all ages: for whom data collection occurred between 30 January 2020 and up to and including 25 May 2021; ANDwho have laboratory-confirmed SARS-COV-2 infection or clinically diagnosed COVID-19.For the 442,643 cases who meet eligibility criteria for this report, selected findings include: median age of 60 years, with an approximately equal (50/50) male:female sex distributionone third of the cohort are at least 70 years of age, whereas 3% are 0-19 years of agethe most common symptom combination in this hospitalised cohort is shortness of breath, cough, and history of fever, which has remained constant over timethe five most common symptoms at admission were shortness of breath, cough, history of fever, fatigue/malaise, and altered consciousness/confusion, which is unchanged from the previous reportsage-associated differences in symptoms are evident, including the frequency of altered consciousness increasing with age, and fever, respiratory and constitutional symptoms being present mostly in those 40 years and above16% of patients with relevant data available were admitted at some point during their illness into an intensive care unit (ICU), which is slightly lower than previously reported (19%)antibiotic use remains very high (61%), although it is lower than previously reported (80%), in those for whom relevant data are available (288,125); in ICU/HDU patients with data available (36,073), 92% received antibioticsuse of corticosteroids was reported for 25% of patients of all types for whom data were available (288,125); in ICU/HDU patients with data available (36,021), 62% received corticosteroidsoutcomes are known for 411,368 patients and the overall estimated case fatality ratio (CFR) is 25% (95%CI 24.8-25), rising to 38% (95%CI 37.5-38.3) for patients who were admitted to ICU/HDU, demonstrating worse outcomes in those with the most severe disease To access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below: https://isaric.org/research/covid-19-clinical-research-resources/evidence-reports/Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://isaric.net/ccp/ https://isaric4c.net/ Funding StatementThis work is supported by grants including: the National Institute for Health Research (NIHR award CO-CIN-01); the Medical Research Council (MRC grant MC_PC_19059); the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at the University of Liverpool in partnership with Public Health England (PHE), Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907); UK Foreign, Commonwealth and Development Office; Wellcome [215091/Z/18/Z]; the Bill & Melinda Gates Foundation [OPP1209135]; and Liverpool Experimental Cancer Medicine Centre (infrastructure support reference C18616/A25153). Contents of the publication are those of the authors and not necessarily reflect those of the funders. Additional funding support can be viewed on the final page of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee approval was given by the WHO Ethics Review Committee (RPC571 and RPC572, 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central - Oxford C Research Ethics Committee in England (Ref 13/SC/0149), the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the UK, which represents the majority of the data. Other institutional and national approvals are in place as per local requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe welcome applications for access to data on the COVID-19 Data Sharing Platform via the Data Access Committee (www.iddo.org/covid-19). https://www.iddo.org/covid-19